Answer
Clarithromycin, a strong CYP3A4 inhibitor, may increase exposure to unconjugated DM4 from mirvetuximab soravtansine (Elahere), increasing adverse-reaction risk; if concomitant use cannot be avoided, patients should be closely monitored for adverse reactions.
Sources for this answer
- ELAHERE 5 mg/mL concentrate for solution for infusionAbbVie Ltd · emc · SmPC §4.5 Interaction with other medicinal products · Version 2Document updated
Sources checked